DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]

Active, not recruiting

Plain-English translation of NCT03529110 on ClinicalTrials.gov ↗ · Source last updated October 2025 · How we translate trials

Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.

Trial locations(164 sites)

United States

UCLA Hematology Oncology, Los Angeles, California

Sharp Memorial Hospital, San Diego, California

University of California San Francisco, San Francisco, California

Innovative Clinical Research Institute, Whittier, California

Washington Cancer Institute, Washington D.C., District of Columbia